Half a decade after Abcam quit its 270 million pound sterling pursuit of Horizon Discovery, the British antibody research expert has potentially found itself on the opposite end of the dealmaking ...

As British research supplies and tools provider Abcam moves toward a potential multibillion-dollar sale, one of the company's founders and major shareholders is pushing back. Dr. Jonathan Milner, an ...

Horizon Discovery has rejected a £270 million ($367 million) takeover bid from Abcam. The gene editing specialist issued a strongly-worded rebuttal of the offer after Abcam went public with its plan, ...

Abcam PLC (NASDAQ:ABCM) is a $3.8 billion market cap biotechnology stock on the Nasdaq Global Select Market. It is moving its primary listing from Londons AIM (previously known as the Alternative ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Abcam has defended the handling of its proposed $5.7bn takeover by Danaher, insisting that the UK life sciences ...

The stock of Abcam PLC (NAS:ABCM, 30-year Financials) is estimated to be fairly valued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the ...

Abcam has ended its pursuit of Horizon Discovery one week after going public about its attempt to buy the gene editing specialist. Cambridge, U.K.-based Abcam painted its proposed £270 million ($367 ...

Activist investor Starboard Value said it supports Abcam's (NASDAQ:ABCM) announcement that it plans to conduct a strategic review, including a potential sale. "We’re pleased that both Abcam and ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Abcam said today it will acquire AxioMx for up to $45 million, in a deal intended to enable the buyer to expand its offerings to customers working in infectious disease, toxins, nucleotides, and ...

Abcam says deal will boost its proteomics products pipeline as well as its manufacturing and development capacity. U.K. antibody and proteomics research products firm Abcam has bought mitochondrial ...

Update 6:32pm: Adds Starboard Value comment. Abcam (NASDAQ:ABCM) founder Jonathan Milner said he suspended his proxy solicitation effort after the biotech company said Friday it would evaluate ...